Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2021
- The Future of Generics
Advertise

Search

Search

Close

Trending

AbbVie and Cugene partner to tackle autoimmune diseases

2nd Annual mRNA-Based Therapeutics Summit

BenevolentAI, AstraZeneca AI-based drug discovery collaboration achieves third milestone

Do pharmaceutical businesses need to rethink what their graduate schemes offer?

AstraZeneca extends oncology partnership with Proteros

systemic mastocytosis

novartis innit

Market Access/ News/ News

NICE says yes to Novartis’ Rydapt for rare blood disorder

Phil Taylor HEOR, NICE, Novartis, rare disease, Rydapt, systemic mastocytosis 0 Comment

Novartis’ Rydapt has become the first and only licensed treatment for rare and life-threatening blood disorder systemic mastocytosis

X

NICE says yes to Novartis’ Rydapt for rare blood disorder

https://pharmaphorum.com/news/nice-says-yes-to-novartis-rydapt-for-rare-blood-disorder/

Blueprint_Ayvakit

Market Access/ News/ News

Blueprint’s latest approval for Ayvakit sets up clash with Novartis

Phil Taylor Ayvakit, Blueprint Medicines, FDA approval, Novartis, Oncology, Rydapt, systemic mastocytosis 0 Comment

Blueprint Medicines has claimed its second FDA approval for Ayvakit, getting the nod for advanced systemic mastocytosis (SM),

X

Blueprint’s latest approval for Ayvakit sets up clash with Novartis

https://pharmaphorum.com/news/blueprints-latest-approval-for-ayvakit-sets-up-clash-with-novartis/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

Lilly’s new drug Mounjaro (tirzepatide ) wins US FDA approval
AstraZeneca, Avillion ‘first-in-class’ combination inhaler shines in Phase 3 trial
AstraZeneca extends oncology partnership with Proteros
Novel drug to tackle inflammatory diseases begins trial
BenevolentAI, AstraZeneca AI-based drug discovery collaboration achieves third milestone

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise
pharmaphorum connect

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com